Clinical Trial Update: Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR. [Phase 2]

View source ↗

Summary

Phase II randomized, open-label study evaluating pegaptanib (Macugen) intravitreal injections plus panretinal photocoagulation for high-risk proliferative diabe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Association for Innovation and Biomedical Research on Light and Image | Conditions: High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I | Phase 2 | Status: COMPLETED